After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 ...

Holy Moley Rocky! Pipsqueak pharmacy wins slam dunk verdict against Big Pharma—re: Ozempic and Wegovy?! Incredible story with ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.

(Reuters) -The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization ...

With the agreement, the Foundation expands its existing collaboration with WHO, committing to a granting frame of up to DKK 380 million over the next four years.

Dividend growth and low payout ratios are key for long-term compounding. Click here for more information on Dividend ...

Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as its legal advisor. Evercore acted as the exclusive financial advisor ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk, the global pharmaceutical leader headquartered in Denmark, has launched a major initiative to combat Thailand's growing obesity crisis, where more than 40% of the population is now ...

In addition to voluntary pledges, WHO member states last year approved an increase in assessed contributions. This year also, ...